Key Findings: Most common: Nausea (43%), diarrhea (33%), vomiting (21%) Unique to retatrutide: Dysesthesia (20.9% @ 12mg in TRIUMPH-4, 8.8% @ 9mg) Discontinuation rate: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 (general obesity population) compared to semaglutide 6.9%, tirzepatide 6.2% Good news: Most side effects peak during dose escalation and improve significantly after week 16 Management: Slow titration, dietary modifications, and proper timing dramatically reduce severity Understanding the Three Categories of Side Effects 1
What if I don't see results by week 8
It is currently being evaluated in clinical trials
This means it works differently from GLP-1-only medicines and dual agonist medicines
Staying informed, maintaining open communication with your healthcare and trial team, and understanding the difference between established evidence and theoretical risk are the most important steps any patient can take
(Try to read the disclosure below.) And while Hims does not claim to be selling Ozempic, as some of the spas Novo sued allegedly did, the company does use the name Ozempic in its advertising
